17,261 trials
Pulmonary Hypertension
Primary: Maximum Change From Baseline in Supine Systolic Blood Pressure (SBP) Within 4 Hours Post-dose at Visit 6 (Week 12) — -20.70; -20.20 mmHg
Urea Cycle Disorders
Primary: Rate of Adverse Events During the Switchover Part of the Study Rate of Adverse Events (Number of Participants Showing Adverse Events) — 4; 2 participants
Head and Neck Neoplasms · Carcinoma, Squamous Cell
Primary: Tumor Shrinkage Before Crossover (Stage 1) of the Trial as Per Investigator Assessment — -3.86; -2.37 millimeter — p=0.7606
Prostate Cancer · Adenocarcinoma of the Prostate
Primary: Endorectal MRI Response After Completion of 6 Cycles of Neoadjuvant Therapy — 0.29 proportion of participants
Hypertension, Pulmonary · Ventricular Dysfunction, Left
Primary: Pulmonary Artery Mean Pressure (PAPmean) at Rest - Change From Baseline to Week 16 — -6.1; -0.8; -4.5; -4.0 mmHg — p=0.1044
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival — 6.9 Months
Epilepsy
Primary: Acute SAE Rate — 6.2 percentage of participants
Actinic Keratosis
Primary: Complete Clearance Rate — 14; 7; 13; 8 participants — p=0.0041
Hematologic Malignancy · Myelodysplastic Syndrome (MDS) · Aplastic Anemia
Primary: The Number of Participants Reaching Primary Endpoint of Absolute Neutrophil Count (ANC) of 500/uL (Engraftment). — 3 participants
Psoriasis Vulgaris
Primary: Change in Total Clinical Score From Baseline to Day 22 — -3.6; -3.7; -4.9; -1.3 units on a scale
Non-small Cell Lung Cancer · Recurrent Non-small Cell Lung Cancer · Stage IIIB Non-small Cell Lung Cancer
Primary: Number of Participants With Objective Response (Complete Response (CR) or Partial Response (PR)) — 1; 12; 17 participants
Male Breast Cancer · Recurrent Breast Cancer · Stage IV Breast Cancer
Primary: Fraction of Patients With Increased Levels of Circulating Endothelial Cells — 30 percentage of participants
Chronic Low Back Pain
Primary: Change From Double-blind Baseline in Chronic Lower Back Pain (CLBP) Intensity by Visual Analog Scale (VAS) — 10.9; 19.9 scores on a scale
Adenocarcinoma of the Pancreas · Recurrent Pancreatic Cancer · Stage IV Pancreatic Cancer
Primary: Median Overall Survival — 4.7 months
Low Back Pain
Primary: Believability of Placebo — 67; 37; 78 percentage of participants — p=<0.01